NASDAQ · VKTX
Healthcare · Biotechnology
$26.09
Up+$1.60 (+6.13%)
Updated Nov 4, 2026, 5:51 PM
SID Score
3.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · VKTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
VKTX closed at $26.09 after 21 trading sessions, down 8.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $26.88 | $27.58 | $25.99 | $26.09 | 2.75M |
| Nov 2, 2026 | $27.25 | $27.90 | $26.54 | $26.83 | 4.43M |
| Oct 30, 2026 | $26.77 | $27.8329 | $26.31 | $27.28 | 5.14M |
| Oct 29, 2026 | $24.375 | $27.76 | $24.375 | $26.86 | 6.75M |
| Oct 28, 2026 | $24.64 | $25.41 | $24.42 | $25.36 | 4.22M |
| Oct 27, 2026 | $24.23 | $24.94 | $23.82 | $24.89 | 3.33M |
| Oct 26, 2026 | $24.40 | $24.8997 | $24.005 | $24.21 | 3.56M |
| Oct 23, 2026 | $25.54 | $25.7426 | $24.36 | $24.40 | 4.68M |
| Oct 22, 2026 | $26.36 | $26.7896 | $25.66 | $25.83 | 3.53M |
| Oct 21, 2026 | $26.83 | $27.29 | $26.31 | $26.38 | 3.3M |
| Oct 20, 2026 | $25.10 | $26.92 | $25.00 | $26.71 | 4.66M |
| Oct 19, 2026 | $25.40 | $25.81 | $25.02 | $25.05 | 3.74M |
| Oct 16, 2026 | $27.17 | $27.345 | $24.94 | $25.17 | 7.58M |
| Oct 15, 2026 | $26.10 | $27.51 | $25.86 | $27.37 | 5.23M |
| Oct 14, 2026 | $26.50 | $26.885 | $25.28 | $25.47 | 6.58M |
| Oct 13, 2026 | $28.20 | $28.20 | $26.60 | $26.65 | 5.74M |
| Oct 12, 2026 | $28.23 | $28.84 | $27.91 | $28.34 | 2.86M |
| Oct 9, 2026 | $27.85 | $28.858 | $27.575 | $28.51 | 4.05M |
| Oct 8, 2026 | $28.37 | $28.49 | $27.05 | $27.73 | 8.73M |
| Oct 7, 2026 | $28.39 | $29.06 | $28.1206 | $28.54 | 5.41M |
| Oct 6, 2026 | $29.49 | $29.715 | $28.1701 | $28.38 | 7.11M |
The latest Smart Investors Daily articles mentioning VKTX.
Company
Market Activity
Research & News
VKTX research
Company profile and research snapshot.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | Canaccord Genuity | Buy | — |
| Oct 20, 2026 | Canaccord Genuity | Buy | — |
| Oct 15, 2026 | UBS | Buy | — |
| Oct 7, 2026 | Truist Securities | Buy | — |
| Sep 23, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Yahoo · Sep 10, 2026
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.
Yahoo · Sep 10, 2026
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
Yahoo · Sep 9, 2026
Viking Therapeutics, Inc. (VKTX) closed at $32.7 in the latest trading session, marking a -2.91% move from the prior day.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VKTX.
